Cargando…
Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) mo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485855/ https://www.ncbi.nlm.nih.gov/pubmed/26170691 http://dx.doi.org/10.2147/OTT.S70524 |
_version_ | 1782378824408760320 |
---|---|
author | Ribera, Josep-Maria Ferrer, Albert Ribera, Jordi Genescà, Eulàlia |
author_facet | Ribera, Josep-Maria Ferrer, Albert Ribera, Jordi Genescà, Eulàlia |
author_sort | Ribera, Josep-Maria |
collection | PubMed |
description | The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) monoclonal antibody blinatumomab can transiently engage cytotoxic T-cells to CD19+ target B-cells inducing serial perforin-mediated lysis. In the first clinical trial, blinatumomab showed efficacy in non-Hodgkin’s lymphomas, but the most important trials have been conducted in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and in ALL with minimal residual disease. Encouraging reports on the activity of blinatumomab in R/R Philadelphia chromosome-negative B-cell precursor ALL led to its approval by the US Food and Drug Administration on December 3, 2014 after an accelerated review process. This review focuses on the profile of blinatumomab and its activity in R/R ALL. |
format | Online Article Text |
id | pubmed-4485855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44858552015-07-13 Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia Ribera, Josep-Maria Ferrer, Albert Ribera, Jordi Genescà, Eulàlia Onco Targets Ther Review The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) monoclonal antibody blinatumomab can transiently engage cytotoxic T-cells to CD19+ target B-cells inducing serial perforin-mediated lysis. In the first clinical trial, blinatumomab showed efficacy in non-Hodgkin’s lymphomas, but the most important trials have been conducted in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and in ALL with minimal residual disease. Encouraging reports on the activity of blinatumomab in R/R Philadelphia chromosome-negative B-cell precursor ALL led to its approval by the US Food and Drug Administration on December 3, 2014 after an accelerated review process. This review focuses on the profile of blinatumomab and its activity in R/R ALL. Dove Medical Press 2015-06-24 /pmc/articles/PMC4485855/ /pubmed/26170691 http://dx.doi.org/10.2147/OTT.S70524 Text en © 2015 Ribera et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Ribera, Josep-Maria Ferrer, Albert Ribera, Jordi Genescà, Eulàlia Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
title | Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
title_full | Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
title_fullStr | Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
title_full_unstemmed | Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
title_short | Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
title_sort | profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485855/ https://www.ncbi.nlm.nih.gov/pubmed/26170691 http://dx.doi.org/10.2147/OTT.S70524 |
work_keys_str_mv | AT riberajosepmaria profileofblinatumomabanditspotentialinthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT ferreralbert profileofblinatumomabanditspotentialinthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT riberajordi profileofblinatumomabanditspotentialinthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT genescaeulalia profileofblinatumomabanditspotentialinthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia |